.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AJ04_Sutimlimab.Sutimlimab .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AJ04_Sutimlimab.Sutimlimab| name: | Sutimlimab | |
| ATC code: | L04AJ04 | route: | intravenous |
| compartments: | 2 | |
| dosage: | 6100 | mg |
| volume of distribution: | 5.6 | L |
| clearance: | 0.25 | L/day |
| other parameters in model implementation | ||
Sutimlimab is a humanized monoclonal antibody that inhibits complement component C1s. It is used primarily in the treatment of cold agglutinin disease (CAD), a rare autoimmune hemolytic anemia. Sutimlimab is approved for use in adults with CAD to prevent hemolysis.
Pharmacokinetic parameters in adult patients (majority female, mean age ~70 years) with cold agglutinin disease after intravenous administration.